Domov › Crohnova choroba › Connecticut
Klinické štúdie Crohnova choroba v štáte Connecticut
14 štúdií pre Crohnova choroba hľadá účastníkov v zariadeniach v štáte Connecticut.
Mestá v štáte Connecticut
Oficiálny text štúdie (anglicky)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Connecticut Clinical Research Institute ( Site 0297), Bristol
Prebieha náborFáza 3
Všetky vekové kategórie · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06651281A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Yale University School of Medicine-Digestive Disease ( Site 5019), New Haven
Prebieha náborFáza 3
Vek 16 až 80 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06430801Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Danbury Hospital, Western Connecticut Health Network /ID# 265556, Danbury
- Yale University School of Medicine /ID# 266786, New Haven
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Medical Research Center of Connecticut, Hamden
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT07499232Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven
- Yale University, New Haven
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Yale University Digestive Disease-Site Number: 8400108, New Haven
Prebieha náborFáza 3
Vek 16 až 80 · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT07184931A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Connecticut Children's Medical Center, Hartford
Prebieha náborFáza 3
Vek 2 až 19 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT04844606A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Medical Research Center of Connecticut, LLC, Hamden
Prebieha náborFáza 4
Vek 18 až 70 · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT06045754A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Connecticut Children's Medical Center, Hartford
Prebieha náborFáza 3
Vek 2 až 17 · Všetky pohlavia · Aktualizované 24. 8. 2026 · NCT05509777Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- Yale University, New Haven
Prebieha nábor
Vek 18 a viac · Všetky pohlavia · Aktualizované 7. 8. 2026 · NCT05230173Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- Yale University School of Medicine, New Haven
Prebieha náborObservačná štúdia
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 8. 2026 · NCT07237516Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD
- Connecticut Children's Medical Center, Hartford
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
Vek 10 až 21 · Všetky pohlavia · Aktualizované 16. 7. 2026 · NCT07224113Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Connecticut Children's Medical Center - Hartford /ID# 262256, Hartford
Prebieha náborFáza 3
Vek 2 až 17 · Všetky pohlavia · Aktualizované 24. 6. 2026 · NCT06332534Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Connecticut Children's Medical Center, Hartford
Prebieha náborFáza 4
Vek 6 až 17 · Všetky pohlavia · Aktualizované 27. 5. 2026 · NCT05781152Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.